Artiva Biotherapeutics

A milestone moment! Artiva Biotherapeutics rang the Nasdaq Closing Bell, marking one year as a public company and reaffirming our mission to make effective, safe, and accessible NK cell immunotherapies available to patients with autoimmune disease and cancer. Our lead program AlloNK® is engineered to amplify the precision of FDA-approved anti-CD20 antibodies, such as rituximab, by adding potent NK-cell antibody-dependent cellular cytotoxicity (ADCC). This combination aims to achieve deeper, durable B-cell depletion for an immune reset in autoimmune disease. AlloNK arrives cryopreserved, non-engineered, and infusion-ready – enabling outpatient dosing without apheresis or gene editing and with a substantially lower risk of cytokine-release syndrome. With our “manufacturing-first” process, a single cord-blood unit has the potential to generate more than 4,000 doses at scale, unlocking biologic-like manufacturing scale and a competitive cost profile. Thank you to Nasdaq for hosting our team and spotlighting the next generation of autoimmune disease treatments. Learn more about #AlloNK: https://lnkd.in/ga5fdcwQ #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune

In Inside Precision Medicine’s June issue, Artiva’s Chief Medical Officer Subhashis Banerjee, MD, outlines our clinical strategy to evaluate AlloNK® across autoimmune diseases through a thoughtfully integrated clinical development plan. By running different trials in parallel, including a Phase 2a basket trial and an investigator-led study in the community, we’re gathering clinical and translational data across lupus nephritis, rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis – with the goal of identifying shared disease mechanisms and guiding future development. Read the Q&A here: https://lnkd.in/gyUCDs4r #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #autoimmune 

NK cell therapies have the potential to reshape the treatment of autoimmune diseases by offering broad B-cell depletion with an improved safety profile and scalable manufacturing. In this latest Q&A with European Pharmaceutical Review Manufacturer, our CEO, Fred Aslan, M.D., shares how Artiva’s off-the-shelf NK cell therapy, AlloNK®, is designed to provide potentially significant advantages over autologous CAR-T. Read more about how AlloNK could unlock broad access to cell therapy for autoimmune diseases: https://lnkd.in/e8m2Xqbq #AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

Artiva will present at the 2025 BIO International Conference on Wednesday, June 18 at 11:45 am in Room 153A. Nicholas Veomett will be sharing the latest on #AlloNK for the treatment of autoimmune diseases. See the conference website for more information: https://lnkd.in/gsi3McyN #BIO2025 #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #autoimmune

May is Arthritis Awareness Month, and our team came together to support the nearly 60 million people affected by arthritis every day. We are proud to raise awareness and stand with those living with chronic pain. #ArthritisAwareness #AutoimmuneDisease #Support #GreenHeartFridays 

Artiva will participate in a fireside chat and 1x1 meetings at the Jefferies 2025 Global Healthcare Conference. Join us for insights into the latest on AlloNK for the treatment of autoimmune diseases. See more details in the press release, including a link to the webcast to watch live or via replay: https://lnkd.in/gc-NvT2R #ARTV #JefferiesHealthcare #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #autoimmune

May 20 is World Autoimmune & Autoinflammatory Arthritis Day, and we take a moment 𝘵𝘰 𝘥𝘳𝘪𝘷𝘦 𝘢𝘸𝘢𝘳𝘦𝘯𝘦𝘴𝘴 for the millions of people living with conditions like rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and systemic sclerosis. Approximately 1 in 10 people, or 450 million people worldwide, are living with an autoimmune or autoinflammatory arthritis disease. For too many patients, the current treatment landscape falls short—relying on broadly immunosuppressive approaches that may not deliver lasting relief or come with long-term risks. This day is a reminder of why Artiva is focused on advancing new therapeutic options for people living with autoimmune arthritis—so they are not only seen and heard, but have the potential for new therapeutic options that could offer lasting improvement. Learn more about #WorldAiArthritisDay: https://lnkd.in/dVyXtdS #AUTOarthritis #LearnArthritis #AiArthritisDay #RheumatoidArthritis #SystemicLupusErythematosus #LupusNephritis #SystemicSclerosis #AutoimmuneArthritis #AutoinflammatoryArthritis #AlloNK #clinicaltrials

We’re pleased to share longer-term data of AlloNK® in combination with rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma at the 28th Annual Meeting of the American Society of Gene & Cell Therapy. These results are comparable to approved autologous CAR-T therapies in aggressive B-NHL—and are among the most durable responses reported for any allogeneic cell therapy in this population to date. AlloNK’s deep B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC), combined with a well-tolerated safety profile and outpatient administration, reinforces its potential not only in hematologic malignancies but also in autoimmune diseases, where durable depletion of pathogenic B-cells is essential. We also have a poster presentation featuring the scalability and consistency of the manufacturing process for AlloNK. The data highlight consistent and high expression of CD16, uniform expansion across greater than 40 manufacturing lots, and high viability and cytotoxicity after four years of shelf life for AlloNK. Read the press release here: https://lnkd.in/gsPrEWh7 #ASGCT2025 #ARTV #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #immunology #immunotherapy #autoimmune #lupus #lupusnephritis #BcellDepletion #Rituximab #targetedtherapy

We join the global lupus community to #MakeLupusVisible — highlighting the challenges patients face and the need for more effective treatment options. At Artiva, we are advancing AlloNK® in combination with monoclonal antibodies in a clinical trial for the treatment of systemic lupus erythematosus and lupus nephritis—a serious kidney complication that affects up to half of all lupus patients. Our goal is to deliver targeted, immune-based therapies that offer meaningful disease control with fewer side effects and can be given in outpatient settings—meeting patients where they are. Learn more about AlloNK: https://lnkd.in/ga5fdcwQ For #WorldLupusDay resources, see this link: https://lnkd.in/dXb_D3mv #AlloNK #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis 

Artiva Biotherapeutics today announced Q1 2025 financial results and recent business highlights. We continue to advance AlloNK® as a potential off-the-shelf treatment for autoimmune disease and cancer, with key clinical programs underway and updated B-NHL data to be presented at ASGCT 2025. Importantly, we’ve initiated the first company-sponsored U.S. trial of an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren’s disease—an important milestone as we work to expand access to cell therapy in the community setting for autoimmune disease treatment. Backed by a strong balance sheet and an experienced development team, we’re well positioned to execute on our vision. Read the pressl release here: https://lnkd.in/gQ2AvASS #ASGCT2025 #ARTV #AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis